EDITAS MEDICINE, INC. (EDIT) Operating Margin
- Operating margin · 12 months: Value -161.39%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -161.39% | Operating income / revenue. Period ending 2026-06-30. $-75.86M ÷ $47.01M × 100 ≈ -161.39% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -75.86M USD | Operating Income (Loss) |
| Revenue | 47.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 84.96M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-75.86M | $47.01M | (m) | $84.96M | (m) | -161.39% |
| 2026-03-31 | $-108.85M | $38.69M | (m) | $80.96M | (m) | -281.32% |
| 2025-12-31 | $-160.01M | $40.52M | (m) | $89.95M | (m) | -394.89% |
| 2025-09-30 | $-198.85M | $46.38M | (m) | $111.16M | (m) | -428.71% |
| 2025-06-30 | $-239.97M | $38.90M | (m) | $139.02M | (m) | -616.86% |
| 2025-03-31 | $-260.32M | $35.84M | (m) | $177.05M | (m) | -726.41% |
| 2024-12-31 | $-251.15M | $32.31M | (m) | $199.25M | (m) | -777.22% |
| 2024-09-30 | $-228.52M | $61.76M | (m) | $220.19M | (m) | -370.02% |
| 2024-06-30 | $-213.02M | $67.03M | (m) | $213.06M | (m) | -317.78% |
| 2024-03-31 | $-185.21M | $69.41M | (m) | $188.63M | (m) | -266.85% |
| 2023-12-31 | $-169.18M | $78.12M | (m) | $177.65M | (m) | -216.56% |
| 2023-09-30 | $-208.66M | $24.61M | (m) | $160.09M | (m) | -847.89% |
| 2023-06-30 | $-216.02M | $19.32M | (m) | $160.91M | (m) | -1118.36% |
| 2023-03-31 | $-226.16M | $22.79M | (m) | $174.79M | (m) | -992.28% |
| 2022-12-31 | $-225.95M | $19.71M | (m) | $174.96M | (m) | -1146.26% |
| 2022-09-30 | $-204.11M | $25.64M | (m) | $160.51M | (m) | -795.92% |
| 2022-06-30 | $-185.85M | $31.80M | (m) | $148.45M | (m) | -584.42% |
| 2022-03-31 | $-187.01M | $25.82M | (m) | $138.55M | (m) | -724.41% |
| 2021-12-31 | $-193.15M | $25.54M | (m) | $142.51M | (m) | -756.13% |
| 2021-09-30 | $-217.41M | $24.49M | (m) | $166.46M | (m) | -887.60% |
| 2021-06-30 | $-169.17M | $81.14M | (m) | $171.11M | (m) | -208.49% |
| 2021-03-31 | $-145.11M | $91.51M | (m) | $165.36M | (m) | -158.57% |
| 2020-12-31 | $-134.84M | $90.73M | (m) | $158.00M | (m) | -148.61% |
| 2020-09-30 | $-108.39M | $91.60M | (m) | $131.28M | (m) | -118.33% |
| 2020-06-30 | $-151.97M | $32.60M | (m) | $120.07M | (m) | -466.10% |
| 2020-03-31 | $-156.28M | $24.18M | (m) | $115.63M | (m) | -646.17% |
| 2019-12-31 | $-140.92M | $20.53M | (m) | $96.90M | (m) | -686.39% |
| 2019-09-30 | $-127.75M | $14.37M | (m) | $81.30M | (m) | -889.27% |
| 2019-06-30 | $-109.42M | $25.04M | (m) | $76.05M | (m) | -437.05% |
| 2019-03-31 | $-113.43M | $30.08M | (m) | $85.20M | (m) | -377.11% |
| 2018-12-31 | $-113.73M | $31.94M | (m) | $90.65M | (m) | -356.10% |
| 2018-09-30 | $-123.92M | (m) | (m) | $97.88M | (m) | (m) |
| 2018-06-30 | $-134.41M | (m) | (m) | $100.84M | (m) | (m) |
| 2018-03-31 | $-120.86M | (m) | (m) | $85.44M | (m) | (m) |
| 2017-12-31 | $-119.93M | (m) | (m) | $83.16M | (m) | (m) |
| 2017-09-30 | $-122.47M | (m) | (m) | $83.57M | (m) | (m) |
| 2017-06-30 | $-116.89M | (m) | (m) | $74.01M | (m) | (m) |
| 2017-03-31 | $-109.98M | (m) | (m) | $67.12M | (m) | (m) |
| 2016-12-31 | $-97.19M | (m) | (m) | $56.98M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-35.31M | (m) | (m) | $18.85M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-12.72M | (m) | (m) | $5.07M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |